Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Before HCT, 88 patients met morphologic criteria for complete remission (CR), ...
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L) In the PETHEMA/GEM2012MENOS65 ...
Please provide your email address to receive an email when new articles are posted on . Healio spoke with John Molina, MD, MEd, about research on the use of minimal residual disease testing in acute ...
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics. Testing for minimal residual disease ...
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: ...
The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...
New tools for monitoring multiple myeloma were a key topic at the European Hematology Society Congress. Advances in drugs and combinations have revolutionized the landscape in multiple myeloma, thus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results